Clinical trial registry record

Peiyuan Guben Tongluo Ointment for Elderly Sarcopenia

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Not Yet Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 20, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07538674
Last registry update
April 20, 2026
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Shanghai Yueyang Integrated Medicine Hospital
Enrollment
60
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
Evidence population
Human clinical study registration
Participants
60
Population
ALL · 60 Years to 80 Years
Duration
2026-04-01 to 2028-12-31
Intervention
nutritional intervention; Exercise; Peiyuan Guben Tongluo Ointment (Ejiao concentrated); Peiyuan Guben Tongluo Ointment (Agarose concentrated)
Comparator
Peiyuan Guben Tongluo Ointment (Agarose concentrated)
Outcomes measured
DXA-measured appendicular skeletal muscle mass — Baseline, week 12, week 24; Upper limb handgrip strength — Up to 24 weeks; Handgrip strength — Baseline, week 12, week 24; Timed Up and Go test (TUG) — Baseline, week 12, week 24; Berg Balance Scale (BBS) — Baseline, week 12, week 24; TCM Syndrome Score — Baseline, week 12, week 24; Peripheral blood white blood cell count — Baseline, week 12; Neutrophil count — Baseline, week 12; Interleukin-2 — Baseline, week 12; Interleukin-6 — Baseline, week 12; Mini Nutritional Assessment (MNA) — Baseline, week 12, week 24; Activities of Daily Living (ADL) Scale — Baseline. week 12, week 24
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Sarcopenia · 100%Title contains controlled term: sarcopenia. Abstract contains controlled term: sarcopenia. Source terminology contains: sarcopenia. Title supplies longevity context: elderly. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

sarcopenia
Open primary sourceExport JSON